DeepSight Technology Unveils NeedleVue Platform at SIR 2026 for Ultrasound Guidance

Advancements in Ultrasound Guidance: The NeedleVue™ Platform by DeepSight Technology

In a significant leap for interventional imaging, DeepSight Technology showcased its groundbreaking NeedleVue™ platform at the Society of Interventional Radiology (SIR) 2026 Annual Meeting held in Toronto. This event marked the launch of the company's diverse NeedleVue™ solutions aimed at enhancing precision ultrasound-guided procedures across various clinical settings.

Introducing the NeedleVue™ Platform

The NeedleVue platform stands out with three primary offerings:

1. NeedleVue™ LiteCart: This is a dedicated standalone system designed specifically for interventional ultrasound. It focuses on real-time visualization of instrument tips and streamlining procedural workflows.

2. NeedleVue™ Embedded (NVE): An original equipment manufacturer (OEM) integrated solution that allows other medical technology platforms to incorporate DeepSight's innovative capabilities directly.

3. NeedleVue™ Mini: Unveiled at SIR 2026, this compact, system-agnostic solution can enhance nearly any existing ultrasound system with advanced guidance functionalities.

Each version utilizes DeepSight's proprietary sensor technology, which is about 50 microns in size. These sensors passively detect ultrasound signals, providing highly accurate, real-time localization of instrument tips even in complex imaging scenarios.

A Vision for the Future

CEO Nader Sadrzadeh emphasized the strategic transition of DeepSight from a product-focused approach to a comprehensive platform strategy. This evolution aims to cater to the diverse needs of clinicians and partners, offering solutions that encompass dedicated systems, seamless integrations, and adaptable add-ons to existing technologies. Sadrzadeh stated, "Our mission is to deliver precision, clarity, and confidence in every procedure and for every patient."

The NeedleVue platform is designed to enhance a wide range of interventional applications, initially targeting ultrasound-guided abdominal biopsies while planning to expand into interventional oncology, vascular procedures, and other minimally invasive image-guided interventions.

Live Demonstrations at SIR 2026

Throughout the SIR 2026 event, DeepSight provided live demonstrations of its NeedleVue platform and facilitated expert-led discussions showcasing how sensor-enabled instruments are transforming the landscape of image-guided care. Attendees had the opportunity to engage directly with the technology and understand its impact on improving patient outcomes.

About DeepSight Technology

DeepSight Technology is at the forefront of redefining interventional imaging through its state-of-the-art sensor-enabled ultrasound solutions. By incorporating proprietary acousto-optic sensing into medical devices, DeepSight strives to allow for real-time, precise tracking and visualization—leading to safer, more efficient, radiation-free procedures for both practitioners and their patients.

The NeedleVue LC1 Ultrasound System currently holds FDA clearance for use only within the United States. Moreover, other NeedleVue platforms are under review for regulatory approval before general marketing.

In conclusion, DeepSight's ambitious plans and innovative offerings present an exciting future for precision interventions, promising to redefine standard practices in healthcare. The combination of technology and a commitment to improving procedural clarity positions DeepSight as a leader in the evolving landscape of interventional imaging.